[go: up one dir, main page]

WO2003045410A1 - Preparation pharmaceutique contenant des ginsenosides conditionnes en microcapsules ou en nanocapsules - Google Patents

Preparation pharmaceutique contenant des ginsenosides conditionnes en microcapsules ou en nanocapsules Download PDF

Info

Publication number
WO2003045410A1
WO2003045410A1 PCT/DE2002/004281 DE0204281W WO03045410A1 WO 2003045410 A1 WO2003045410 A1 WO 2003045410A1 DE 0204281 W DE0204281 W DE 0204281W WO 03045410 A1 WO03045410 A1 WO 03045410A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
preparation according
ginsenosides
therapeutic treatment
microapplication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/004281
Other languages
German (de)
English (en)
Inventor
Ernes-Elme Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDIWIRK GmbH
Original Assignee
MEDIWIRK GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDIWIRK GmbH filed Critical MEDIWIRK GmbH
Priority to AU2002358418A priority Critical patent/AU2002358418A1/en
Publication of WO2003045410A1 publication Critical patent/WO2003045410A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Definitions

  • the invention relates to a pharmaceutical preparation with an active substance enclosed in a microapplication sleeve.
  • This new carrier system can give the active ingredient completely new properties with regard to its effects and properties.
  • the active ingredients are usually in the form of tablets and capsules, which are administered orally. Such orally administered applications first pass through a liver passage before they are distributed through the bloodstream in the organism. With this route of application, the active ingredient can largely be broken down into effective secondary products before it reaches the intended site of action (cells, tissue, organ). As a result, it is not uncommon for a higher dose or multiple injections or oral administrations per day to be maintained in order to maintain a therapeutically effective concentration in the body.
  • the liposomes are generally divided into three basic types, Small Unilamellar Vesicles (SUV), Large Unilamellar Vesicles (LUV) and Multilamellar Large Vesicles (MLV). These basic types differ in their size and in their shell structure. Small unilamellar vesicles are understood to be liposomes with a diameter of up to 50 nm, while large unilamellar vesicles with a diameter of 50 nm to 3 ⁇ m and multilamellar vesicles with a diameter of 100 nm to several micrometers are attributed.
  • nanoparticles So-called solid lipid nanoparticles (SLN) viewed (Dirk Hoffmann op. cit.).
  • the object of the invention is to provide a further pharmaceutical composition with an active ingredient packaged in a microapplication shell for various new therapeutic uses with minimal stress on the organism.
  • the object is achieved by a pharmaceutical preparation having the features of claim 1.
  • the invention has the particular advantage that for the first time the therapeutic potential of active substances in the ginseng plant, ginsenosides, is tapped in the form of "drug targeting".
  • the new form of application enables a variety of new uses for pharmaceutical preparations, including medicinal products containing ginsenosides, and allows the different pharmacological effects of ginsenosides to be exploited effectively.
  • the ginseng plant is known as a medicinal plant through many homeopathic uses.
  • the ingredients of the ginseng extract are said to have very different effects. Appropriate liquid and solid preparations should strengthen the organism's natural resistance and accelerate its recovery after resilience.
  • the ginsenosides can be brought directly to the target cell by means of the application route according to the invention.
  • the ginsenosides are thus protected against the attack of body fluids and thus against decay when they enter the organism. They can develop their full effectiveness at the destination. Because of the “packaging” in microapplication casings, the pharmacological compositions containing ginsenosides can also be administered intravenously for the first time.
  • the microapplication shells are formed by liposomes or nanoparticles or the microapplication sheath has a multilayer membrane.
  • a further preferred embodiment of the invention provides that the ginsenosides from the group aglycon (20S) -protopanaxadiol with the ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, the notoginsenosides R4, Rs1 and Rs2 and the malonylginsenosides Rb1, Rc and Rd and / or the group Aglykon (20S) -protopanaxtriol with the ginsenosides Re, Rf, Rg1 and the notoginsenoside R1 and / or the aglykon oleanolic acid with the ginsenosides Ro, also known as Chikusetsusasaponin-V, are.
  • the pharmaceutical preparation containing at least one of the ginsenosides R1, R4, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rs1, Rs2, Ro or Chikusetsusasaponin-V or on several of the ginsenosides mentioned in a mixture or in combination with other active substances linked via ligands coupled to the microapplication shell.
  • ginsenosides were isolated as individual components in an HPLC system, packaged in liposomes and used for pharmacological studies.
  • a pharmaceutical preparation can be made available whose use is suitable for the therapeutic treatment of liver tumors, cirrhosis of the liver and other chronic liver diseases.
  • compositions according to the invention containing ginsenoside Ro are suitable for the treatment of hepatitis.
  • Preparations according to the invention with a content of the ginsenosides Rb1 and Rg1 are preferably suitable for the therapy of aggressions, those with a content of the ginsenoside of the type Rb for therapy for heart diseases and preparations with a content of the ginsenosides Rb1 and Rg3 for the protection of nerve cells.
  • lipid composition to be used for the packaging in accordance with its organ-specific targeting, as is evident from the known prior art, and to pack the ginsenoside or the mixture of ginsenosides with the relevant organ-specific effect therein in accordance with the targeting strategy.
  • the ginsenosides can also be packaged according to the technical solutions resulting from DE 198 52 928 C1.
  • the solutions according to the invention offer completely new and inexpensive starting points for the therapeutic field of application of the individual ginsenosides and their compositions and the increase in the therapeutic efficiency of pharmaceutical preparations by their concentration at the site of action.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une préparation pharmaceutique contenant un ginsenoside conditionné dans une micro-enveloppe et l'utilisation de cette préparation. Cette invention permet de mettre en valeur le potentiel thérapeutique d'agents actifs de la plante de ginseng, les ginsenosides, sous forme d'un </= ciblage de médicament >/= . Les ginsenosides sont ainsi introduits directement à l'intérieur de la cellule cible. Ce mode d'administration les protège de l'attaque des fluides corporels et donc de leur décomposition lors de leur introduction dans l'organisme. Par conséquent, ils peuvent développer toute leur efficacité sur le site cible. Leur conditionnement dans des micro-enveloppes permet aux ginsenosides d'être pour la première fois également administrés sous forme intraveineuse.
PCT/DE2002/004281 2001-11-19 2002-11-18 Preparation pharmaceutique contenant des ginsenosides conditionnes en microcapsules ou en nanocapsules Ceased WO2003045410A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002358418A AU2002358418A1 (en) 2001-11-19 2002-11-18 Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10158281.1 2001-11-19
DE2001158281 DE10158281A1 (de) 2001-11-19 2001-11-19 Pharmazeutisches Präparat

Publications (1)

Publication Number Publication Date
WO2003045410A1 true WO2003045410A1 (fr) 2003-06-05

Family

ID=7707206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004281 Ceased WO2003045410A1 (fr) 2001-11-19 2002-11-18 Preparation pharmaceutique contenant des ginsenosides conditionnes en microcapsules ou en nanocapsules

Country Status (3)

Country Link
AU (1) AU2002358418A1 (fr)
DE (1) DE10158281A1 (fr)
WO (1) WO2003045410A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026924A1 (fr) * 2004-09-08 2006-03-16 Zelin Li Utilisation de ginsenoside dans le traitement du sida
KR100842070B1 (ko) 2007-04-09 2008-06-30 박준원 나노 플래티늄 진세노사이드 입자 및 그의 제조 방법
WO2008086739A1 (fr) * 2007-01-16 2008-07-24 Chengdu Di'ao Jiuhong Pharmaceutical Factory Utilisation d'une saponine d'acide ursolique et d'une saponine d'acide oléanolique pour préparer un médicament destiné à accroître la quantité des leucocytes et/ou des plaquettes sanguines
EP2455084A4 (fr) * 2009-07-16 2013-06-05 Cj Cheiljedang Corp Composition anti-hypertensive contenant une fraction enrichie en ginsénosides
CN106924427A (zh) * 2017-03-24 2017-07-07 成都海青生物科技有限公司 一种可有效治疗消渴病的中药组合物及其制备方法
CN108014118A (zh) * 2017-12-25 2018-05-11 上海中医药大学 一种三七皂苷Ft1的用途
CN113896757A (zh) * 2020-07-07 2022-01-07 中国科学院上海药物研究所 一类五环三萜类碳苷化合物及其制备方法和用途
WO2022052996A1 (fr) * 2020-09-10 2022-03-17 上海交通大学 Utilisations de composés de protopanaxadiol dans le traitement de la douleur, et de la dépendance physique, de la dépendance psychologique et de l'addiction à des substances addictives

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234956A1 (en) * 2005-04-15 2006-10-19 Amersen Bioscience International, Inc. Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
DE102005052005B4 (de) * 2005-10-31 2007-10-18 Infineon Technologies Ag Prozessor-Anordnung
CN100438876C (zh) * 2006-06-09 2008-12-03 上海中药创新研究中心 20(s)-原人参二醇在制备抗抑郁药物中的应用
CN101264096B (zh) * 2007-03-12 2011-11-09 中国医学科学院药物研究所 人参皂苷Rg1在制备生精产品中的应用
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2179042A (en) * 1985-07-22 1987-02-25 Takeda Chemical Industries Ltd Ginsenoside-Rd
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO2000028972A2 (fr) * 1998-11-17 2000-05-25 Novosom Gmbh Nanocapsules et leur procede de production
WO2000074656A1 (fr) * 1999-06-07 2000-12-14 Bio Dar Ltd. Formulations micro-encapsulees et a liberation prolongee a base d'herbes medicinales
EP1142903A1 (fr) * 1998-12-22 2001-10-10 Japan Science and Technology Corporation AGENTS PROTECTEURS DE CELLULES CEREBRALES OU NERVEUSES CONTENANT DU GINSENOSIDE Rb 1?
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee
WO2002069980A2 (fr) * 2001-03-07 2002-09-12 Cambridge University Technical Services Limited Composes pharmaceutiquement efficaces et utilisation de ces composes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5646817A (en) * 1979-09-27 1981-04-28 Ryuta Ito Saponin antitumor agent
JPH09241166A (ja) * 1996-03-06 1997-09-16 Kureha Chem Ind Co Ltd Ｈｓｐ６０ファミリーに属するタンパク質のジンセノサイド類含有合成抑制剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2179042A (en) * 1985-07-22 1987-02-25 Takeda Chemical Industries Ltd Ginsenoside-Rd
US5776460A (en) * 1995-06-07 1998-07-07 Man Ki Park Processed ginseng product with enhanced pharmacological effects
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO2000028972A2 (fr) * 1998-11-17 2000-05-25 Novosom Gmbh Nanocapsules et leur procede de production
EP1142903A1 (fr) * 1998-12-22 2001-10-10 Japan Science and Technology Corporation AGENTS PROTECTEURS DE CELLULES CEREBRALES OU NERVEUSES CONTENANT DU GINSENOSIDE Rb 1?
WO2000074656A1 (fr) * 1999-06-07 2000-12-14 Bio Dar Ltd. Formulations micro-encapsulees et a liberation prolongee a base d'herbes medicinales
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee
WO2002069980A2 (fr) * 2001-03-07 2002-09-12 Cambridge University Technical Services Limited Composes pharmaceutiquement efficaces et utilisation de ces composes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG Z-G ET AL: "Current status and future direction of Chinese herbal medicine", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 347 - 348, XP004386169, ISSN: 0165-6147 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026924A1 (fr) * 2004-09-08 2006-03-16 Zelin Li Utilisation de ginsenoside dans le traitement du sida
WO2008086739A1 (fr) * 2007-01-16 2008-07-24 Chengdu Di'ao Jiuhong Pharmaceutical Factory Utilisation d'une saponine d'acide ursolique et d'une saponine d'acide oléanolique pour préparer un médicament destiné à accroître la quantité des leucocytes et/ou des plaquettes sanguines
US8394776B2 (en) 2007-01-16 2013-03-12 Chengdu Di'ao Jiuhong Pharmaceutical Factor Use of ursolic acid saponin,oleanolic acid saponin in preparation of increasing leucocytes and/or platelet medicine
KR100842070B1 (ko) 2007-04-09 2008-06-30 박준원 나노 플래티늄 진세노사이드 입자 및 그의 제조 방법
EP2455084A4 (fr) * 2009-07-16 2013-06-05 Cj Cheiljedang Corp Composition anti-hypertensive contenant une fraction enrichie en ginsénosides
CN106924427A (zh) * 2017-03-24 2017-07-07 成都海青生物科技有限公司 一种可有效治疗消渴病的中药组合物及其制备方法
CN108014118A (zh) * 2017-12-25 2018-05-11 上海中医药大学 一种三七皂苷Ft1的用途
CN113896757A (zh) * 2020-07-07 2022-01-07 中国科学院上海药物研究所 一类五环三萜类碳苷化合物及其制备方法和用途
WO2022052996A1 (fr) * 2020-09-10 2022-03-17 上海交通大学 Utilisations de composés de protopanaxadiol dans le traitement de la douleur, et de la dépendance physique, de la dépendance psychologique et de l'addiction à des substances addictives

Also Published As

Publication number Publication date
DE10158281A1 (de) 2003-05-28
AU2002358418A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
DE69613463T3 (de) Filmbildende pharmazeutische zusammensetzungen zur transdermalen verabreichung
DE60117711T2 (de) Antineoplastisches arzneimittel
WO2003045410A1 (fr) Preparation pharmaceutique contenant des ginsenosides conditionnes en microcapsules ou en nanocapsules
DE60004348T2 (de) Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate
DE69215999T2 (de) Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs
EP1150681A2 (fr) Composition pharmaceutique contenant de la desoxypeganine utilisee pour le traitement de la dependance a la nicotine
WO1992004036A1 (fr) Extrait de kawa-kawa, son procede de production et son utilisation
DE20119321U1 (de) Pharmazeutisches Präparat
DE19726871C1 (de) Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE19530708C2 (de) Pharmazeutisches Präparat mit trypanoziden Eigenschaften
EP2136816B1 (fr) Oléyl-phosphocholine
DE3851389T2 (de) Liposom-Freisetzungssystem für Opoid-Analgetika.
DE69724228T2 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
Oladimeji et al. Phytochemical and antimicrobial studies on some Nigerian medicinal plants
DE69717961T2 (de) Verwendung eines flavonoid enthaltenden extraktes der planze euphorbia prostrata zur herstellung eines medikamentes zur behandlung von anoraktalen oder kolonbeschwerden
WO2008017331A2 (fr) Forme médicamenteuse perorale pour contraception
DE69825322T2 (de) Topische carbamazepin-formulierungen und deren verwendung
DE60202299T2 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
DE69526111T2 (de) Zusammensetzung zur behandlung von endometriose, welche ein salz eines edelmetalles und mel cum sale enthält
US12350335B2 (en) Homeopathic topical composition
DE60216979T2 (de) Synergistische hepatoprotektive Zusammensetzung aus trans-Tetracos-15-ensäure und Apocynin und Verwendung davon
WO1998017229A2 (fr) Medicament
DE202024104792U1 (de) Indolderivat-Formulierung für gezielte krebsbekämpfende Wirkung von Chemotherapeutika
WO2023242339A1 (fr) Composition comprenant de la pétasine et de l&#39;isopétasine ayant un effet hépatoprotecteur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002792600

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Ref document number: 2002792600

Country of ref document: EP

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP